Targeted therapy

Targeted therapy is cancer treatment that aims at specific molecules on or in cancer cells instead of attacking all fast-dividing cells. In Intro to Pharmacology, it connects drug action, biomarkers, and personalized medicine.

What is targeted therapy?

Targeted therapy is a cancer treatment approach in Intro to Pharmacology that uses drugs or biologic agents to interfere with a specific molecule, receptor, or signaling pathway that a tumor depends on. Instead of broadly damaging all rapidly dividing cells, the drug is chosen to hit a particular target linked to the cancer's growth, survival, or spread.

That target might be a mutated protein, an overactive growth receptor, or a signaling step that keeps the cancer cell dividing. Once the drug binds or blocks that target, the cell may stop growing, lose the signal that keeps it alive, or become easier for the immune system to remove. This is why targeted therapy is tied closely to pharmacodynamics, because the effect depends on what the drug does to a specific molecular target.

A lot of targeted therapy starts with tumor testing. If a cancer has a known marker or mutation, the treatment can be matched more precisely to that profile. That is where pharmacogenomics and personalized medicine show up in the course, because the point is to match therapy to the biology of the patient’s tumor, not just the tissue where the cancer started.

Two common forms are small molecule inhibitors and monoclonal antibodies. Small molecules often enter cells and block enzymes or signaling proteins from the inside, while monoclonal antibodies usually bind to targets on the cell surface or to circulating factors outside the cell. The same general goal applies in both cases, but the route and target location are different.

Targeted therapy is not the same thing as “no side effects.” It usually has a different side effect pattern than traditional chemotherapy, and those effects often reflect the target being blocked in some normal tissues too. In a class example, a breast cancer or lung cancer case may ask you to identify why genetic testing was ordered before treatment, or why a specific marker made one drug a better choice than another.

Why targeted therapy matters in Intro to Pharmacology

Targeted therapy shows how modern pharmacology moves from broad killing to mechanism-based treatment. It ties together receptor binding, signaling pathways, and tumor biology, so you can see why one drug works for one cancer type but not another.

This term also connects directly to pharmacogenomics and precision medicine. When a tumor has a marker such as a specific mutation or overexpressed receptor, the treatment decision can be based on that molecular detail. That is a big shift from the older idea of treating every tumor the same way just because it grows quickly.

In cancer chemotherapy units, targeted therapy helps you compare treatment strategies. Traditional antineoplastic agents often hit dividing cells widely, which is why hair loss, nausea, and bone marrow effects show up so often. Targeted drugs may still cause serious adverse effects, but the pattern is more tied to the pathway being blocked.

If you can explain why a tumor biomarker changes the drug choice, you are already using the main pharmacology skill this term is built around.

How targeted therapy connects across the course

Biomarkers

Biomarkers are the clues that tell you whether a tumor has a target a drug can hit. In targeted therapy, a biomarker may be a mutated protein, receptor, or other measurable feature that predicts response. If a cancer does not show the right marker, the same drug may not work well, which is why testing often comes before treatment selection.

Precision Medicine

Precision medicine is the broader approach that targeted therapy fits into. Instead of using the same treatment for every patient with a cancer type, you match the drug to the molecular features of the disease. Targeted therapy is one of the clearest examples of that idea because the treatment depends on the tumor's biology.

Monoclonal Antibodies

Monoclonal antibodies are one major way targeted therapy is delivered. These lab-made proteins bind to a specific antigen or receptor, often on the surface of cancer cells, and can block signaling or flag the cell for immune attack. They are different from small molecule drugs, which usually work inside the cell.

Pharmacokinetics

Pharmacokinetics matters because a targeted drug still has to reach the tumor at the right concentration. Absorption, distribution, metabolism, and excretion all affect whether enough drug gets to the target and how long it stays active. A drug can be highly specific in theory but still fail if it never reaches the tissue well.

Is targeted therapy on the Intro to Pharmacology exam?

A quiz item or case study may give you a cancer diagnosis, a mutation result, or a drug name and ask why targeted therapy fits better than standard chemotherapy. You might need to identify the target, connect it to the tumor's growth pathway, or explain why a biomarker test was ordered before treatment.

On problem sets, the move is usually to trace the mechanism: drug binds target, signaling changes, tumor growth slows, and side effects may shift compared with a nonselective antineoplastic agent. In essay questions, you may compare targeted therapy with chemotherapy by focusing on specificity, expected adverse effects, and the reason genetic testing matters before choosing a drug.

Targeted therapy vs Combination Chemotherapy

These are often mixed up because both are cancer treatment plans and both can involve more than one drug. Targeted therapy refers to the mechanism, a drug aimed at a specific molecular target. Combination chemotherapy refers to using multiple cancer drugs together, usually to improve effectiveness or reduce resistance, and those drugs are not always target-specific.

Key things to remember about targeted therapy

• Targeted therapy is cancer treatment designed to hit a specific molecular target linked to tumor growth or survival.

• It is closely connected to tumor testing, because the drug choice often depends on biomarkers or mutations found in the cancer.

• Small molecule inhibitors and monoclonal antibodies are two common targeted therapy types, and they reach the target in different ways.

• Compared with traditional chemotherapy, targeted therapy is usually more selective, but it can still cause side effects if normal tissues share the target.

• In Intro to Pharmacology, this term sits at the intersection of drug mechanism, pharmacogenomics, and cancer treatment.

Frequently asked questions about targeted therapy

What is targeted therapy in Intro to Pharmacology?

Targeted therapy is a cancer treatment that blocks a specific molecule or pathway the tumor uses to grow. In Intro to Pharmacology, it shows how drug action can be matched to tumor biology instead of using a broad cytotoxic approach.

How is targeted therapy different from chemotherapy?

Chemotherapy usually affects many rapidly dividing cells, which is why it can damage healthy tissue as well as cancer. Targeted therapy is designed around a specific marker or pathway, so it is more selective, though not side-effect free.

Why do doctors test tumors before using targeted therapy?

Testing looks for biomarkers or mutations that predict whether a drug will work. If the tumor does not have the target, the therapy may not help, so the test helps match the treatment to the cancer's molecular profile.

Is targeted therapy the same as immunotherapy?

Not always. Some targeted therapies are antibodies, and some can influence immune activity, but the core idea is specific molecular targeting. Immunotherapy is a broader category that uses the immune system to fight cancer.